Comparison of Three-sided and Single-sided Mattress Pancreaticojejunostomy in Pancreatoduodenectomy

Launched by TOKAI UNIVERSITY · Mar 3, 2025

Keywords

ClinConnect Summary

Pancreatoduodenectomy (PD) is one of the most difficult and invasive surgeries, with a 30-50% complication rate even at high volume centers. In particular, if a postoperative pancreatic fistula (POPF), a failure of the pancreaticojejunostomy (PJ) suture, occurs, pancreatic juice containing powerful digestive enzymes leaks into the abdominal cavity, which can develop into serious complications such as intraperitoneal abscesses and postpancreatectomy hemorrhage. To reduce the incidence of POPF post-PD, many clinical studies have been reported on PJ methods. Currently, the original/modified Bl...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients scheduled for pancreaticoduodenectomy who have been determined to have a soft pancreas.
• • 2. Preoperative CT images show that the pancreatic duct diameter at the planned site of pancreatic resection is 5mm or less.
• • 3. ECOG Performance Status (PS) is 0-1.
• • 4. Age 18 years or older.
• • 5. Function of major organs (bone marrow, heart, liver, kidneys, lungs, etc.) is maintained.
• • 6. Patients have sufficient judgment to understand the content of the research, and written consent has been obtained from the individual.
• Exclusion Criteria:
• • 1. Patients with severe ischemic heart disease
• • 2. Patients with liver cirrhosis or active hepatitis
• • 3. Patients with respiratory distress requiring oxygen due to interstitial pneumonia or pulmonary fibrosis
• • 4. Patients undergoing dialysis due to chronic renal failure
• • 5. Patients requiring combined resection of surrounding organs
• • 6. Patients requiring arterial reconstruction of the superior mesenteric artery, common hepatic artery, celiac artery, etc.
• • 7. Patients with active duplicate cancers that may affect adverse events or overall survival
• • 8. Patients taking oral steroids for a long period that may affect adverse events
• • 9. Patients with insufficient decision-making ability
• • 10. Other subjects deemed inappropriate by the principal investigator or investigator